Oto vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 38)
Oto logo

Oto

EmergingHealthcare

General

London digital CBT app for tinnitus with DEFINE Trial evidence showing 86% benefit in one month; £2.8M seed competing with Widex and ReSound for 750M global tinnitus sufferers needing accessible specialist care.

AI VisibilityBeta
Overall Score
D38
Category Rank
#455 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
36
Perplexity
33
Gemini
40

About

Oto is a London-based digital health company providing clinically validated, app-based CBT (cognitive behavioral therapy) treatment for tinnitus — the persistent ringing, buzzing, or hissing in the ears that affects 15% of the global population (750 million+ people) with no pharmaceutical cure — delivering structured therapeutic programs designed by tinnitus specialists that help patients manage and reduce tinnitus distress through evidence-based psychological and sound therapy techniques. Founded and backed with £2.8 million in seed funding raised in 2022, Oto demonstrated in the DEFINE Trial (the largest randomized controlled trial for any digital tinnitus program) that 86% of users experience measurable benefits within one month of the program.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

38
Overall Score
93
#455
Category Rank
#1
85
AI Consensus
80
stable
Trend
stable
36
ChatGPT
94
33
Perplexity
89
40
Gemini
94
36
Claude
92
37
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.